Jazz Pharmaceuticals plc
JAZZ
$103.58
$5.805.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.46% | 7.53% | 8.52% | 6.95% | 1.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.46% | 7.53% | 8.52% | 6.95% | 1.03% |
| Cost of Revenue | 12.32% | 21.40% | 9.26% | 12.68% | -2.41% |
| Gross Profit | -1.48% | 6.43% | 8.43% | 6.30% | 1.31% |
| SG&A Expenses | 46.15% | 11.00% | 5.66% | -0.68% | 18.06% |
| Depreciation & Amortization | -0.82% | 4.85% | 1.66% | 2.08% | 3.97% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.94% | 10.58% | -0.62% | 3.09% | 12.98% |
| Operating Income | -124.74% | -2.55% | 50.94% | 26.52% | -43.92% |
| Income Before Tax | -3,642.05% | 118.13% | 101.24% | 72.15% | -105.45% |
| Income Tax Expenses | -252.64% | -75.02% | 69.19% | -26.02% | 176.15% |
| Earnings from Continuing Operations | -533.06% | 102.98% | 46.48% | 61.40% | -121.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -533.06% | 102.98% | 46.48% | 61.40% | -121.06% |
| EBIT | -124.74% | -2.55% | 50.94% | 26.52% | -43.92% |
| EBITDA | -48.29% | 0.82% | 27.02% | 14.27% | -22.14% |
| EPS Basic | -549.38% | 109.82% | 50.53% | 64.25% | -121.38% |
| Normalized Basic EPS | -329.30% | 2.11% | 106.82% | 75.18% | -68.38% |
| EPS Diluted | -549.38% | 118.51% | 59.66% | 64.28% | -122.57% |
| Normalized Diluted EPS | -329.30% | 11.90% | 127.11% | 81.82% | -63.26% |
| Average Basic Shares Outstanding | -2.49% | -3.26% | -2.69% | -1.73% | -1.51% |
| Average Diluted Shares Outstanding | -2.49% | -11.73% | -11.39% | -5.32% | -15.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |